2,521
edits
Difference between revisions of "Industrial fermentation"
Jump to navigation
Jump to search
→NovelYeast bv
Stef Denayer (talk | contribs) |
Lars Krause (talk | contribs) |
||
| Line 184: | Line 184: | ||
=== '''NovelYeast bv''' === | === '''NovelYeast bv''' === | ||
{{Infobox provider-industrial fermentation|Company=NovelYeast bv| | {{Infobox provider-industrial fermentation|Company=NovelYeast bv|Agitator=Shake flasks, static tubes with magnetic stirring|Feedstock=1G and 2G feedstocks|Other=Construction of cell factories with recombinant DNA technology|Reactor material=Glass|Microorganism=Saccharomyces cerevisiae, other yeast species, Trichoderma|Controlled parameters=Standard parameters|Biosafety lavel=BSL-1|Aeration=Aerobic, semi-anaerobic|Webpage=https://www.linkedin.com/in/johan-thevelein-aab60a10/|Capacity=Lab-scale|TRL=3-5|Technology category=Industrial fermentation|Technology name=Yeast fermentation to biofuels and bio-based chemicals. Protein production|Contact=johan.thevelein@novelyeast.com|Country=Belgium|Product=Biofuels and bio-based chemicals, proteins, specialty sugars, specialty chemicals}} | ||
NovelYeast bv was founded in 2019 by Prof. Johan Thevelein (KU Leuven and VIB) to continue his R&D activities after his retirement in 2020 as emeritus. The company focusses on the development and industrial implementation of yeast cell factories for the production of biofuels, bio-based chemicals as well as specialty sugars and ingredients with first- and second-generation feedstocks. It also develops cell factories for the production of specific proteins for food applications and enzymes for saccharification of lignocellulosic biomass. In addition, it uses yeast as a tool for biomedical and agroindustrial applications, including yeast probiotics and anti-cancer drugs selected by screening in yeast. NovelYeast has several R&D service collaborations with companies world-wide. | NovelYeast bv was founded in 2019 by Prof. Johan Thevelein (KU Leuven and VIB) to continue his R&D activities after his retirement in 2020 as emeritus. The company focusses on the development and industrial implementation of yeast cell factories for the production of biofuels, bio-based chemicals as well as specialty sugars and ingredients with first- and second-generation feedstocks. It also develops cell factories for the production of specific proteins for food applications and enzymes for saccharification of lignocellulosic biomass. In addition, it uses yeast as a tool for biomedical and agroindustrial applications, including yeast probiotics and anti-cancer drugs selected by screening in yeast. NovelYeast has several R&D service collaborations with companies world-wide. | ||